Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Salarius Pharmaceuticals, Inc. | slrx12312019-322ex906pfoce.htm |
| EX-32.1 - EX-32.1 - Salarius Pharmaceuticals, Inc. | slrx12312019-321ex906peoce.htm |
| EX-31.2 - EX-31.2 - Salarius Pharmaceuticals, Inc. | slrx12312019-312expfocerti.htm |
| EX-31.1 - EX-31.1 - Salarius Pharmaceuticals, Inc. | slrx20191231ex-311.htm |
| EX-4.11 - EX-4.11 - Salarius Pharmaceuticals, Inc. | slrx12312019descriptionofr.htm |
| 10-K - 10-K - Salarius Pharmaceuticals, Inc. | flks-20201231.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1)Registration Statement (Form S-8 No. 333-201816) pertaining to the 2014 Equity Incentive Plan, 2015 Equity Incentive Plan and 2015 Employee Stock Purchase Plan of Salarius Pharmaceuticals, Inc. (formerly known as Flex Pharma, Inc.);
(2)Registration Statement (Form S-8 Nos. 333-210283, 333-216534, 333-223499, 333-230104 and 333-246310) pertaining to the 2015 Equity Incentive Plan and 2015 Employee Stock Purchase Plan of Salarius Pharmaceuticals, Inc. (formerly known as Flex Pharma, Inc.);
(3)Registration Statement (Form S-3 No. 333-231010 and 333-252169) of Salarius Pharmaceuticals, Inc. (formerly known as Flex Pharma, Inc.);
(4)Registration Statement (Form S-1 No. 333-235879) of Salarius Pharmaceuticals, Inc.
of our report dated March 18, 2021, with respect to the consolidated financial statements of Salarius Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Salarius Pharmaceuticals, Inc. for the year ended December 31, 2020.
/s/ Ernst & Young LLP
Houston, Texas
March 18, 2021